Global pharma expects bumper year

Global pharma expects bumper year

Increasing footprints in Vietnam in 2023, multinational corporations continue to eye stronger local partnerships to bring more new innovative medicines and vaccines to the local market in 2024 and beyond.
Legal landscape adjusted for global pharma groups

Legal landscape adjusted for global pharma groups

Multinational corporations operating in Vietnam are expected to benefit from new legal changes in the months to come, after years of delay.
Multinational pharma groups keen on robust partnerships

Multinational pharma groups keen on robust partnerships

After making gains in 2022, multinational corporations will prioritise strengthening local partnerships to support their ambition of transforming the treatment landscape – but they are also pleading for further legal clarity.
Pharma groups step up competition

Pharma groups step up competition

More international pharma and medical device businesses are rushing to venture further in Vietnam, anticipating wide growth potential.
The legal adaption measures expected from pharma groups

The legal adaption measures expected from pharma groups

Multinational corporations in Vietnam are expecting changes in drug rules to make more business and investment progress. Tran Ngoc Anh, representative of the US-ASEAN Business Council, discussed with VIR’s Bich Thuy the current barriers and expectations stemming from legal adjustments.
Top pharma groups bet on high growth

Top pharma groups bet on high growth

A decade of innovation is in sight for Vietnam’s largest pharmaceutical companies, as long as quick adaption and changes in business strategy are carried out.
Swings and roundabouts for pharma groups so far in 2021

Swings and roundabouts for pharma groups so far in 2021

With risks from interruption of the medical ingredient supply chain and losses in the hospital channel, the Vietnamese pharma industry experienced a topsy-turvy first half of 2021, with potential growth set to focus on mergers and acquisitions.
Targets being tweaked by prepared pharma

Targets being tweaked by prepared pharma

There remains caution over interruption in the ingredient supply chain in Vietnam’s lucrative pharmaceutical industry, but new strategies to intensify growth potential ahead will ensure pharma groups maintain their profitability moving forward.
Fresh rules to tackle pharma misconduct

Fresh rules to tackle pharma misconduct

Violations in the pharmaceutical industry are seemingly never-ending, with Young Il Pharm, USV Private, and Armepharco being among recent prominent names. However, future wrongdoings may be better resisted when new stricter rules come into effect next month.
Pharma groups to profit from virus?

Pharma groups to profit from virus?

The top 10 global pharmaceutical companies are being scrutinised and advised not to prevent or delay a vaccine for COVID-19 from reaching vulnerable people to gain profits, triggering global concerns over their social responsibility.